Atsushi Otsuka

Articles:  1-1 of 1

  • Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

    藤澤 康弘 , Taku Fujimura , Yota Sato , Kayo Tanita , Yumi Kambayashi , Atsushi Otsuka , Yasuhiro FUJISAWA , Koji Yoshino , Shigeto Matsushita , Takeru Funakoshi , Hiroo Hata , Yuki Yamamoto , Hiroshi Uchi , Yumi Nonomura , Ryota Tanaka , Megumi Aoki , Keisuke Imafuku , Hisako Okuhira , Naoko Wada , Hiroyuki Irie , Takanori Hidaka , Akira Hashimoto , Setsuya Aiba

    Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs sur …

    Frontiers in Oncology (8), 530, 2018-11

    IR 

Page Top